Participants 38 97 5
opioid use during prescription opioid dependence treatment.
Participants 468 521 3
outpatient treatment of prescription opioid addiction
Participants 559 710 8
participants with prescription opioid dependence who received 12 weeks of buprenorphine-naloxone and counseling in a multi-site clinical trial (N=353).
Participants 1355 1595 5
Individual differences in drug reinforcement value, as indicated by pre-treatment allocation of economic resources to drugs, reflects propensity for continued opioid use during treatment among individuals with prescription opioid addiction.
